Hepatitis C antiviral therapy is currently progressing at a rapid pace. Various generic products have been launched in India, Bangladesh and other places one after another. For example, if you buy the generic drug “Ji II” from India for the treatment of hepatitis C, a course of treatment costs only 9,000 yuan. At present, the cost of long-acting interferon (Paroxetine/Pelargonidone) therapy in China is about RMB 60,000-70,000 yuan. Unlike previous Indian “copycat” antineoplastic drugs, this time the Indian generic companies have reached an agreement with the original drug company.In September 2014, seven Indian generic companies were authorized to produce a generic version of Gilead’s Sovaldi. These companies are required to pay Gilead a commission based on sales. And these generics can be sold to 91 developing countries. But China is not among the countries that sell at a low price, because in Gilead’s view, China is no longer a developing country. In China, the Patent Law stipulates that Chinese pharmaceutical companies are not allowed to produce “generic drugs” during the patent protection period. Although according to the “patent compulsory licensing” system similar to that of India, the Chinese government can also, for the purpose of protecting “public health”, authorize some Chinese pharmaceutical companies to use the patented technology of foreign manufacturers to produce generic drugs during the patent protection period, the Patent Law has been enacted for 30 years now, and Chinese pharmaceutical companies are no longer a developing country. However, in the 30 years since the enactment of the Patent Law, China has not implemented a single case of “patent compulsory licensing”. As long as they do not have the approval of the State Drug Administration (SDA), drugs sold publicly in the domestic market are illegal. Gregg Alton, executive vice president of Gilead, said in a statement, “Sovaldi is priced at$300 a bottle (28 tablets) in India, which is the company’s pricing for low-income countries.” Gilead has different pricing strategies for different countries. Michelle, Gilead’s director of global public relations, told Economic Observer, “The final price will depend on each country’s treatment needs, healthcare infrastructure, and the government’s determination and commitment to scaling up effective therapies for the treatment of the hepatitis C virus.” Judging from the current situation, even if Gilead is allowed to enter China in the future, the price of its Hepatitis C drugs may far exceed the number of Indian prices.